TQB2930

· Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TQB2930, covering 2026-02-02 to 2026-02-02. Get the full timeline:

Most recent: Clinical Trial Update: TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer [Phase 3]